 |
SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant...
More shoppers are seeking out Aussie businesses online. A com.au domain name says your business is local. * 70% of respondents to a surv...
If you are looking to register your company so you can finally be a legitimate business, with all the right licences and paperwork, then you will be...
Selecting the right business process management (BPM) software is crucial for streamlining operations and improving efficiency within your organiz...
You have a breakthrough idea and a killer business plan for your startup. A talented workforce is ready to take on any challenges in the market. It ...
AI-powered personalised real estate platform Soho.com.au, has announced today it is collaborating with Sotheby’s International Realty to showcase ...
Essay writing can be a daunting task to not just students, but virtually anyone who is required to pen down one. Aside the time needed to sit and ...